STRIIVING: switching to abacavir/dolutegravir/lamivudine fixed dose combination (ABC/DTG/3TC FDC) from a PI, INI or NNRTI based regimen maintains HIV suppression at week 48 Article

Web of Science: 000395394300154
Open Access Industry Collaboration International Collaboration

Cited authors

  • Lake, J. E.; Trottier, B.; Garcia-Diaz, J.; Edelstein, H.; Kumar, P.; Bredeek, U. F.; Loutfy, M.; Brennan, C.; Koteff, J.; Wynne, B.; Hopking, J.; Aboud, M.

Publication date

  • 2016


  • 19